Literature DB >> 11403963

The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner.

G Rammes1, R Rupprecht, U Ferrari, W Zieglgänsberger, C G Parsons.   

Abstract

The type 3 serotonin (5-HT(3)) receptor is a ligand-gated ion channel. In concentration-clamp experiments, we investigated the effects of the uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists memantine, amantadine and MRZ 2/579 on 5-HT receptors stabley expressed in HEK-293 cells and on native 5-HT(3) receptors in the N1E-115 cell line. All agents antagonized serotonin (10 microM)-induced inward currents with similar potency to that reported for NMDA receptors. This effect was characterized by inducing a pronounced receptor desensitization, and was probably non-competitive and voltage-independent. In contrast, (S)-ketamine was much weaker as an antagonist of 5-HT(3) receptors than NMDA receptors. Similar effects on 5-HT(3) receptors have been reported previously for a variety of anti-depressants and it is possible that the clinical anti-depressant effects reported for both memantine and amantadine are mediated, at least in part, by antagonistic effects at 5-HT(3) receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403963     DOI: 10.1016/s0304-3940(01)01872-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  55 in total

Review 1.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

2.  N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers.

Authors:  Suchitra Krishnan-Sarin; Stephanie S O'Malley; Nicholas Franco; Dana A Cavallo; Meghan Morean; Julia Shi; Brian Pittman; John H Krystal
Journal:  Alcohol Clin Exp Res       Date:  2015-02-09       Impact factor: 3.455

3.  The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.

Authors:  Patricia Spilman; Olivier Descamps; Olivia Gorostiza; Clare Peters-Libeu; Karen S Poksay; Alexander Matalis; Jesus Campagna; Alexander Patent; Rammohan Rao; Varghese John; Dale E Bredesen
Journal:  Brain Res       Date:  2013-12-31       Impact factor: 3.252

Review 4.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

Review 5.  Cardiovascular effects of drugs used to treat Alzheimer's disease.

Authors:  Laurence Guy Howes
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

Review 6.  Alzheimer's Disease Therapeutic Approaches.

Authors:  Maria Revi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  The effects of the glutamate antagonist memantine on brain activation to an auditory perception task.

Authors:  Heidi van Wageningen; Hugo A Jørgensen; Karsten Specht; Tom Eichele; Kenneth Hugdahl
Journal:  Hum Brain Mapp       Date:  2009-11       Impact factor: 5.038

Review 8.  The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential.

Authors:  P Murali Doraiswamy
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

9.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

Review 10.  Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.

Authors:  Stuart J Thomas; George T Grossberg
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.